

**North of Tyne, Gateshead and North Cumbria  
Area Prescribing Committee**  
[www.northoftyneapc.nhs.uk](http://www.northoftyneapc.nhs.uk)  
**Tuesday 14<sup>th</sup> January 2020 12:30 pm**  
**Cobalt conference centre, Level 2**  
**Northumbria Healthcare NHS Foundation Trust**  
**Northumbria House**  
**7-8 Silver Fox Way**  
**Cobalt Business Park**  
**North Shields**  
**NE27 0QJ**

**AGENDA**

1.	Apologies for absence	
2.	Declarations of interest	
3.	Appeals against previous decision <ul style="list-style-type: none"> <li>• None</li> </ul>	
4.	Minutes from the meeting 8/10/19 Decision summary from 8/10/19	Enc.1. Enc.2.
5.	Matters arising not on the agenda	
6.	APC Action log <ul style="list-style-type: none"> <li>• December 2019 update</li> </ul>	Enc.3.
7.	Report from the Formulary sub-group <ul style="list-style-type: none"> <li>• Draft minutes from meeting held on 21/11/19</li> <li>• Draft decision summary from meeting held on 21/11/19</li> </ul>	Enc.4. Enc.5.
8.	Report from the Medicines Guidelines and Use Group <ul style="list-style-type: none"> <li>• Draft minutes from meeting held on 2/12/20</li> <li>• Updated terms of reference</li> <li>• Guidance agreed to retire: <ul style="list-style-type: none"> <li>○ Management of heart failure</li> </ul> </li> <li>• Guidance/documents approved: <ul style="list-style-type: none"> <li>○ Catheter formulary</li> <li>○ Catheter info sheet v1.0</li> <li>○ Blood glucose test strips v2.0</li> <li>○ Vitamin B12</li> <li>○ Swallowing difficulties v2.0.</li> <li>○ Acne guideline v2.1.</li> <li>○ Vitamin D QRG v2.0.</li> </ul> </li> </ul>	Enc.6. Enc.7.  Enc.8. Enc.9. Enc.10. Enc.11. t/f Enc.12. Enc.13. Enc.14.
9.	CNTW - letter from Sunderland/South Tyneside APC	Enc.15.
10.	Standardising pathways and Guidelines - AHSN project	Enc.16.
11.	Opiate/pain management sub-group <ul style="list-style-type: none"> <li>• Update from meeting held on 20/11/19</li> <li>• Qtr2. Data</li> </ul>	Enc.17.

12.	<b>RMOCs</b> <ul style="list-style-type: none"> <li>• Prescribing and commissioning of sodium oxybate in adult patients (≥19 years) with narcolepsy with cataplexy.</li> <li>• Regional Medicines Optimisation Committee (RMOc) Position Statement : Oral vitamin B supplementation in alcoholism November 2019</li> <li>• RMOc Shared Care Guidance consultation (which includes the following): <ul style="list-style-type: none"> <li>○ a definition of shared care</li> <li>○ letter templates to support shared care communications</li> <li>○ a shared care monograph</li> <li>○ a list of medicines deemed suitable for shared care.</li> </ul> </li> </ul>	Enc.18. Enc.19.  Email 19/12/19 Enc.20a &20b
13.	ICS update	
14.	Northern (NHS) Treatment Advisory Group (NTAG). <a href="http://ntag.nhs.uk/">http://ntag.nhs.uk/</a> <ul style="list-style-type: none"> <li>• Next meeting February 2020</li> </ul>	
15.	NICE Technology Appraisals published since last meeting <ul style="list-style-type: none"> <li>• TA604 <a href="#">Idelalisib for treating refractory follicular lymphoma</a></li> <li>• TA605 <a href="#">Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea</a></li> <li>• TA606 <a href="#">Lanadelumab for preventing recurrent attacks of hereditary angioedema</a></li> <li>• TA607 <a href="#">Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease</a></li> <li>• TA608 <a href="#">Ibrutinib with rituximab for treating Waldenström's macroglobulinaemia (terminated appraisal)</a></li> <li>• TA609 <a href="#">Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)</a></li> <li>• TA610 <a href="#">Pentosan polysulfate sodium for treating bladder pain syndrome</a></li> <li>• TA611 <a href="#">Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer</a></li> <li>• TA612 <a href="#">Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab</a></li> <li>• TA613 <a href="#">Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy</a></li> <li>• TA614 <a href="#">Cannabidiol with clobazam for treating seizures associated with Dravet syndrome</a></li> <li>• TA615 <a href="#">Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome</a></li> <li>• TA616 <a href="#">Cladribine for treating relapsing–remitting multiple sclerosis- technology appraisal guidance</a></li> <li>• HST12 <a href="#">Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2</a></li> </ul>	
16.	NHS England <ul style="list-style-type: none"> <li>• Specialised Services circulars <ul style="list-style-type: none"> <li>○ SSC2083 - Specialised Commissioning Update</li> <li>○ SSC2084 - NICE TA 591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant</li> <li>○ SSC2085 - NHS England Treatment Criteria for NICE TA 587 guidance: Lenalidomide plus dexamethasone for previously untreated multiple myeloma</li> </ul> </li> </ul>	Enc.21. 

	<ul style="list-style-type: none"> <li>○ SSC2086 - NICE TA 586 guidance: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib</li> <li>○ SSC2087 - Clinical Commissioning Urgent Policy Statement: Antivirals for adults with recent onset (acute) hepatitis. Ref: 170135P</li> <li>○ SSC2089 - NICE TA FAD: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer</li> <li>○ SSC2090 - NICE TA guidance [TA343] Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia</li> <li>○ SSC2091 - Paclitaxel as albumin-bound nanoparticles (nab-paclitaxel) for breast cancer patients</li> <li>○ SSC2092 - Specialised Commissioning Update</li> <li>○ SSC2096 - Change in atezolizumab dosing schedule: implications for currently funded indications for adults with non-small cell lung cancer and urothelial cancers</li> <li>○ SSC2099 - Specialised Commissioning Update - December</li> <li>○ SSC2100 - Changes to Blueteq registration requirements for patients receiving neo-adjuvant and adjuvant pertuzumab for HER2-positive early-stage breast cancer</li> <li>○ SSC2101 - NICE Technology Appraisal Final Appraisal Determination: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (including a review of technology appraisal no. 381)</li> <li>○ SSC2104 - NICE Technology Appraisal Final Appraisal Determination - palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer</li> <li>○ SSC2105 - Isatuximab in combination with pomalidomide and dexamethasone for the 4th line treatment of adult patients with relapsed and or refractory multiple myeloma</li> <li>○ SSC2107 - Maternal intravenous immunoglobulin administration for prevention of alloimmune fetal and neonatal haemochromatosis disease NHS England Reference -1864</li> <li>○ SSC2111 - Technology Appraisal 614 and 615 - Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome and Dravet syndrome</li> <li>○ SSC2113 - NHS England update on selected providers for the new Multiple Sclerosis Management Service for Children</li> <li>○ SSC2114 - NICE Highly Specialised Technology HST11 - Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations</li> </ul>	
17.	Chairman's action	
18.	Any other business	
19.	Date, time and venue of next meetings: Cobalt conference centre, Level 2 Northumbria Healthcare NHS Foundation Trust Northumbria House 7-8 Silver Fox Way Cobalt Business Park	

North Shields NE27 0QJ	
Tuesday, 21st April 2020 12:30 pm room 4	
Tuesday, 7th July 2020 12:30 pm room 4	
Tuesday, 13th October 2020 12:30 pm room to confirm	
Tea/coffee will be available from 12:15 pm	